Last reviewed · How we verify

Telmisartan + Rosuvastatin — Competitive Intelligence Brief

Telmisartan + Rosuvastatin (Telmisartan + Rosuvastatin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II receptor antagonist, Statin. Area: Cardiovascular.

phase 3 Angiotensin II receptor antagonist, Statin AT1 receptor, HMG-CoA reductase Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Telmisartan + Rosuvastatin (Telmisartan + Rosuvastatin) — Daewon Pharmaceutical Co., Ltd.. Telmisartan is an angiotensin II receptor antagonist that blocks the action of angiotensin II, a potent vasoconstrictor, thereby lowering blood pressure. Rosuvastatin is a statin that inhibits HMG-CoA reductase, a key enzyme in cholesterol synthesis, thereby lowering LDL cholesterol.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Telmisartan + Rosuvastatin TARGET Telmisartan + Rosuvastatin Daewon Pharmaceutical Co., Ltd. phase 3 Angiotensin II receptor antagonist, Statin AT1 receptor, HMG-CoA reductase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin II receptor antagonist, Statin class)

  1. Daewon Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Telmisartan + Rosuvastatin — Competitive Intelligence Brief. https://druglandscape.com/ci/telmisartan-rosuvastatin. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: